
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KV1.6 CRISPR/Cas9 KO Plasmid (h) | sc-409638 | 20 µg | $397.00 |
KCNA6 encodes the voltage-gated potassium channel subunit KV1.6, a Shaker-related delayed rectifier that shapes action potential repolarization and regulates neuronal firing frequency. By contributing to membrane potential stability and excitability, KV1.6 influences synaptic signaling and network oscillations, integrating into electrical signaling processes controlled by voltage-dependent ion flux. KV1-family channels participate in pathways that modulate neurotransmitter release, axonal conduction, and activity-dependent excitability, and altered potassium conductance is broadly relevant to disorders of neuronal hyperexcitability. Variation or dysregulated expression in voltage-gated K⁺ channel genes has been associated with neurological phenotypes, supporting the use of KCNA6 perturbation to study excitability-linked mechanisms in human cellular models.
KV1.6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KCNA6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KCNA6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KCNA6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KV1.6 protein expression.
This CRISPR knockout system enables efficient generation of KCNA6-deficient cell models for investigation of KV1.6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.